New Drug R&D

Pirfenidone Tablets

Product Name: Pirfenidone Tablets
Dosage Forms: Tablet
Strengths: 0.2 g
Mechanism of Action:
Idiopathic Pulmonary Fibrosis is a chronic fibrotic and inflammatory pulmonary disease affected by the synthesis and release of pro-inflammatory cytokines including tumour necrosis factor-alpha (TNF-α) and interleukin-1-beta (IL-1β) and pirfenidone has been shown to reduce the accumulation of inflammatory cells in response to various stimuli. Pirfenidone attenuates fibroblast proliferation, production of fibrosis-associated proteins and cytokines, and the increased biosynthesis and accumulation of extracellular matrix in response to cytokine growth factors such as, transforming growth factor-beta (TGF-β) and platelet-derived growth factor (PDGF).
It is indicated for the treatment of Idiopathic pulmonary fibrosis (IPF).
Processing Number: CXHL1000286, CXHL1000287
Status: Has gotten the clinical trial permission (2012L01570, 2012L01571) in July, 2012.
Copyright @ Beijing Hope Pharmaceutical Co., Ltd.